

Resolution



of the Federal Joint Committee (G-BA) on an Application for Exemption from the Benefit Assessment Because of Insignificance According to Section 35a, Paragraph 1a SGB V “Other Diagnostic Agents”

of 18 June 2020

At its session on 18 June 2020, the Federal Joint Committee decided to remedy the objection of a pharmaceutical company received on 25 October 2019 against the resolution of the Federal Joint Committee of 17 October 2019, on the application of the pharmaceutical company for exemption of a medicinal product with a new active ingredient from the benefit assessment according to Section 35a, paragraph 1a SGBV and to grant the application:

The pharmaceutical company was exempted from the obligation to submit evidence according to Chapter 5, Section 5 of the Rules of Procedure of the Federal Joint Committee (VerfO) and the proprietary medicinal product concerned was exempted from the benefit assessment according to the provisions of Chapter 5 VerfO.

Berlin, 18 June 2020

Federal Joint Committee
in accordance with Section 91 SGB V
The Chair

Prof. Hecken